Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19...
Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma
The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...
Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...
Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D
Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...
Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial
China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...
China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.
China and the United States are nearing an agreement that would allow Chinese firms to...
Shandong Releases Off-Label Drug Use Consensus, Expanding Clinical Guidance
The Shandong Pharmaceutical Association (SPA) has released the “Shandong Province Expert Consensus on Off-label Drug...
ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...
InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D
China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...
NMPA Releases 57th Batch of Reference Drugs for Generic Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 57th batch of reference drugs for...
J&J MedTech Joins China’s Surgical Training Program to Skill Up Surgeons
The National Institute of Hospital Administration (NIHA) and the National Health Commission (NHC) launched the...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
NMPA Reclassifies Omeprazole Tablets from Prescription to OTC Status
The National Medical Products Administration (NMPA) announced that omeprazole enteric-coated tablets have been reclassified from...
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
Acchrom Tech Raises USD 14.45M in Angel Round Led by BioTrack Capital to Expand Chromatography Solutions
Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an...
JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results...
Everest Medicines CEO Resigns as Trodelvy Sale Completed
China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...